| Literature DB >> 34825163 |
Sonja Rutten1,2, Erwin E H van Wegen3, Ires Ghielen1,2, Bridget Schoon1,2, Odile A van den Heuvel1,2.
Abstract
INTRODUCTION: Anxiety disorders occur in approximately one third of people with Parkinson's disease (PD), and have a major impact on patient and caregiver wellbeing. In order to better understand and diagnose anxiety in PD patients, we investigated the generalizability of the results of a previous factor analysis on anxiety symptoms to a sample of PD patients with neuropsychiatric symptoms.Entities:
Keywords: Anxiety; Factor analysis; Neuropsychiatry; Non-motor symptoms; Parkinson’s disease; Replication; Symptom interaction
Year: 2021 PMID: 34825163 PMCID: PMC8605274 DOI: 10.1016/j.prdoa.2021.100117
Source DB: PubMed Journal: Clin Park Relat Disord ISSN: 2590-1125
Clinical and demographic characteristics (N = 123).
| Mean | SD | Range | |
|---|---|---|---|
| % Female | 38.2 | ||
| Age | 66.1 | 9.8 | 34–86 |
| Disease duration (years) (n = 85) | 8.4 | 6.9 | 0–29 |
| MoCA score | 23.8 | 4.7 | 5–30 |
| UPDRS-III score (n = 109) | 27.3 | 14.8 | 1–76 |
| Total BAI score | 20.3 | 11.4 | 0–55 |
| Total BDI score | 18.2 | 9.3 | 1–47 |
| % Use dopaminergic medication | 93.5 | ||
| % Treatment of psychiatric symptoms prior to PD diagnosis | 49.6 |
Psychiatric diagnoses as given by assessing psychiatrist (N = 123)
| Diagnosis given (DSM-IV or -5) | % |
|---|---|
| 8.1 | |
| 52.9 | |
| Due to somatic disorder (PD) | 41.5 |
| Panic disorder | 6.5 |
| Generalized anxiety disorder | 3.3 |
| Social anxiety disorder | 1.6 |
| 41.4 | |
| Due to somatic disorder (PD) | 25.2 |
| Persistent depressive disorder (dysthymia) | 0.8 |
| Major depressive disorder | 15.4 |
| 31.7 | |
| 16.3 | |
| 12.9 | |
| 15.4 |
all patients fulfilling criteria for this DSM category had an impulse control disorder.
Fig. 1Graphical display of the results of the PCA of the BAI. Factor loadings, Eigenvalues (ʎ) and percentage of explained variance (PEV) are displayed.
Results of multiple linear regression analyses of the BAI total score and score on subscales of the BAI with the BDI, MoCA and UPDRS-III, adjusted for gender, age and use of PD medication.
| DEPENDENT VARIABLE → INDEPENDENT VARIABLE ↓ | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| B | 95% CI of B | β | B | 95% CI of B | β | B | 95% CI of B | β | B | 95% CI of B | β | B | 95% CI of B | β | |
| (constant) | 11.915 | −10.559 to 34.389 | 4.854 | −4.602 to 14.310 | 3.154 | −2.525 to 8.834 | 3.621 | −0.955 to 8.197 | 2.992 | −5.719 to 11.704 | |||||
| BDI | 0.691 | 0.503 to 0.880 | 0.246 | 0.167 to 0.326 | 0.008 | −0.039 to 0.054 | 0.035 | −0.009 | −0.048 to 0.029 | −0.046 | 0.004 | −0.069 to 0.077 | 0.011 | ||
| MoCA | −0.339 | −0.786 to 0.108 | −0.141 | −0.177 | −0.365 to −0.011 | −0.182 | −0.001 | −0.114 to 0.112 | −0.002 | −0.045 | −0.136 to 0.046 | −0.117 | 0.069 | −0.105 to 0.242 | 0.095 |
| UPDRS-III | −0.003 | −0.130 to 0.123 | −0.004 | −0.027 | −0.080 to 0.026 | −0.087 | 0.009 | −0.023 to 0.041 | 0.058 | −0.015 | −0.041 to 0.010 | −0.124 | 0.005 | −0.045 to 0.054 | 0.019 |
| Gender | 2.729 | −0.856 to 6.313 | 0.117 | 0.993 | −0.515 to 2.501 | 0.106 | 0.049 | −0.857 to 0.955 | 0.011 | 0.122 | −0.607 to 0.852 | 0.033 | −0.507 | −1.896 to 0.882 | −0.072 |
| Age | 0.032 | −0.179 to 0.243 | 0.028 | 0.020 | −0.069 to 0.108 | 0.042 | −0.008 | −0.062 to 0.045 | −0.037 | −0.024 | −0.067 to 0.019 | −0.131 | 0.023 | −0.058 to 0.105 | 0.067 |
| PD MEDICATION | −2.074 | −9.182 to 5.034 | −0.045 | −0.493 | −3.483 to 2.498 | −0.027 | −0.855 | −2.651 to 0.941 | −0.095 | 1.170 | −0.277 to 2.618 | 0.158 | 0.018 | −2.737 to 2.773 | 0.001 |
| R2 | 0.402 | 0.349 | 0.013 | 0.047 | 0.012 | ||||||||||
BAI = Beck Anxiety Inventory; BDI = Beck Depression Inventory; UPDRS-III = Unified Parkinson’s Disease Rating Scale – part three (motor examination); MoCA = Montreal Cognitive Assessment, B = regression coefficient, 95% CI of B = 95% confidence intervals of B, β = standardized regression coefficient.
= p < 0.05.